公开(公告)号：US11939397B2

公开(公告)日：2024-03-26

申请号：US17058870

申请日：2019-05-29

Applicant: Novartis AG

Inventor： Michael Didonato ,  Christoph Erkel ,  Anna Galkin ,  Scott Glaser ,  Klaus Felix Hartlepp ,  Yong Jia ,  Alexandra Kraus ,  Christian Cho-Hua Lee ,  Sarah Michelle Rue ,  Jian Shi ,  Xenia Karola Wezler

IPC: C07K16/40 ,  A61K39/00 ,  A61K39/395 ,  A61K45/06 ,  A61P35/00 ,  C07K16/28

CPC classification number: C07K16/40 ,  A61K39/39541 ,  A61K39/3955 ,  A61K45/06 ,  A61P35/00 ,  C07K16/2818 ,  A61K2039/505 ,  A61K2039/507 ,  C07K2317/24 ,  C07K2317/33 ,  C07K2317/55 ,  C07K2317/92

Abstract: Provided herein are antibodies or antigen-binding fragments thereof, e.g., monoclonal antibodies or antigen binding fragments thereof, that specifically bind to ENTPD2 (e.g., human ENTPD2 protein), and methods of using these antibodies or antigen-binding fragments. The present invention also relates to combination therapies comprising an anti-human ENTPD2 antibody or antigen binding fragment and at least one additional therapeutic agent, and methods of using these combination therapies.